DNA Therapeutics develops targeted drugs against resistant cancer with a lead IMP demonstrating good safety & antitumor activity in patients
DNA Therapeutics is a spin-off of the Institut Curie, INSERM, CNRS, MNHN. It develops a new class of targeted drugs against resistant cancer based on a novel concept Dbait. Its lead DT01 has already shown antitumor activity with good safety & tolerance in patients (phase I/IIa). The ability of DT01 to improve the efficacy of existing cancer therapies without additional toxicity makes it a promising drug to address the unmet needs in many cancers.